

Not for release, or for publication or distribution, directly or indirectly in or into the United States, Australia, Hong Kong, Canada, Japan, New Zealand or South Africa.

PRESS RELEASE
Lund, Sweden, 4 April 2012



BioInvent's rights issue oversubscribed

BioInvent International (OMXS:BINV) announced today that its preferential rights issue has been oversubscribed. The subscription period in the rights issue was concluded on 30 March 2012. The new shares will bring BioInvent SEK 104.8 million before transaction costs.

Svein Mathisen, CEO and President of BioInvent, comments: "It is very rewarding for us that our rights issue did receive good support from our shareholders. We are now free to focus on the business opportunities which arise as we publish results from three clinical trials later this year."

The final result of the rights issue show that 6,209,737 shares, representing 92.4 per cent of the offered shares were subscribed for by the exercise of subscription rights. Additionally, subscription forms concerning 1,531,125 shares, representing 22.8 per cent of the offered shares have been received for subscription without preferential right. The subscription price was SEK 15.60 and BioInvent's shareholders had the right to subscribe for one new share for every ten existing shares.

Those who have subscribed for shares without preferential right will be allotted shares according to the principles outlined in the prospectus, which was published on 13 March 2012. Notifications regarding allotment are expected to be distributed on or around 10 April 2012. Only those who are allotted shares will be notified.

New shares subscribed for by the exercise of subscription rights are expected to start trading on NASDAQ OMX Stockholm on 12 April 2012. Trading in shares subscribed without preferential right is expected to start on 26 April 2012.

As a consequence of the preferential rights issue BioInvent will increase its share capital by SEK 3,360,262.50 to SEK 36,962,891. The number of shares will increase by 6,720,525 to 73,925,782 shares. Mannheimer Swartling served as legal advisor to BioInvent and Redeye arranged for a group of investors guaranteeing the rights issue.

--END--

To the editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product

pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by n-CoDeR®, a proprietary antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB

Svein Mathisen
President & CEO
Phone: +46 (0)46 286 85 67
Mobile: +46 (0)708 97 82 13
E-mail: svein.mathisen@bioinvent.com

Sten Westerberg
Vice President, Investor Relations
Phone: +46 (0)46 286 85 52
Mobile: +46 (0)768 68 50 09
E-mail: sten.westerberg@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263,
Visiting address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Phone: +46 (0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, Servier, UCB and XOMA. More information is available at www.bioinvent.com.

The information was submitted for publication at 8.30 a.m. CET, on 4 April, 2012.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in BioInvent International AB. Any invitation to the persons concerned to subscribe for shares in BioInvent is made only through the prospectus that BioInvent made public on 13 March 2012.

This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Hong Kong, Canada, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares will be registered under the United States Securities Act of 1933 ("**Securities Act**") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the

registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

This press release may contain forward-looking statements which reflect BioInvent's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.